MAPT and Cognitive impairment: Adding the LB status to the established Aβ and tau biomarker profile13, we aimed to study the independent effects of LB and AD pathologies on cognitive and neurological deficits in memory clinic patients with mild cognitive impairment (MCI) or dementia from two well-characterized cohorts (the Swedish BioFINDER-1 (n = 398) and BioFINDER-2 (n = 485) studies).